Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (171-180 of 205) with videos related to

Pageof 21
Sort By:
Epigenetics & Chromatin|May 30, 2018
Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X TenShalima S Nair, Phuc-Loi Luu, Wenjia Qu, et al.
Cancers|December 16, 2020
Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia PatientsUlf Schmitz, Jaynish S Shah, Bijay P Dhungel, et al.
Blood|August 9, 2011
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemiaNicola Esposito, Irene Colavita, Concetta Quintarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.
Blood|September 2, 2025
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutationsNaranie Shanmuganathan, David T Yeung, Carol Wadham, et al.
Blood|November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsHagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Leukemia|January 8, 2021
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
Leukemia|June 10, 2021
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
Annals of Internal Medicine|February 21, 2018
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label StudyFrançois-Xavier Mahon, Carla Boquimpani, Dong-Wook Kim, et al.
Blood|December 15, 2025
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST TrialJorge E Cortes, Timothy P Hughes, Jianxiang Wang, et al.
Pageof 21

Showing results (171-180 of 205) with videos related to

Sort By:
Pageof 21
Epigenetics & Chromatin|May 30, 2018
Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X TenShalima S Nair, Phuc-Loi Luu, Wenjia Qu, et al.
Cancers|December 16, 2020
Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia PatientsUlf Schmitz, Jaynish S Shah, Bijay P Dhungel, et al.
Blood|August 9, 2011
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemiaNicola Esposito, Irene Colavita, Concetta Quintarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.
Blood|September 2, 2025
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutationsNaranie Shanmuganathan, David T Yeung, Carol Wadham, et al.
Blood|November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsHagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Leukemia|January 8, 2021
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
Leukemia|June 10, 2021
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
Annals of Internal Medicine|February 21, 2018
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label StudyFrançois-Xavier Mahon, Carla Boquimpani, Dong-Wook Kim, et al.
Blood|December 15, 2025
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST TrialJorge E Cortes, Timothy P Hughes, Jianxiang Wang, et al.
Pageof 21